INDV Indivior Plc

TIDMINDV

RNS Number : 5861T

Indivior PLC

09 January 2017

Indivior PLC (the 'Company')

Shaun Thaxter, CEO of Indivior PLC is presenting at the JP Morgan Healthcare Conference on January 11(th) , 2017 at 4pm Pacific time (12am UK time). A link to the webcast of the presentation is provided and the slides can be downloaded in pdf format on the Company's website at www.indivior.com. In addition, a playback of the presentation will be available for 3 months.

About Indivior

Indivior is a global specialty pharmaceutical company with a 20-year legacy of leadership in patient advocacy, health policy and evidence-based best practice models that have revolutionized modern addiction treatment. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its robust, global opioid dependence portfolio, Indivior has a strong pipeline of product candidates designed to both expand treatments in opioid dependence and address other chronic diseases of addiction - including alcohol use disorder, cocaine intoxication and schizophrenia. Headquartered in the United States in Richmond, VA, Indivior employs more than 900 individuals globally and its portfolio is available in over 40 countries worldwide. Its name is a fusion of the words individual and endeavor and its logo radiates the company's patient-centered holistic focus on expanding access to high-quality treatment services for addiction worldwide. For additional product information, please visit www.indivior.com

Investor Enquiries

Tom Corran, IR Director, Indivior PLC

+44 1753 423965

tom.corran@indivior.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCSSAFMMFWSESF

(END) Dow Jones Newswires

January 09, 2017 08:00 ET (13:00 GMT)

Indivior (LSE:INDV)
Historical Stock Chart
From Apr 2024 to May 2024

Indivior (LSE:INDV)
Historical Stock Chart
From May 2023 to May 2024